MDR resistance treatment and novel pharmaceutically active rimin

Details MDR resistance treatment and novel pharmaceutically active rimin MDR resistance treatment and novel pharmaceutically active rimin

1996-10-28

1998-06-09

Berch, Mark L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

544348, C07D24146, A61K 31495

Patent

active

057634432

ABSTRACT:
The invention concerns the new use of riminophenazines in the treatment of a patient who has built up, or could build up, resistance to a therapeutically active substance, such as a patient requiring treatment for cancer. The riminophenazine conveniently may be of the general formula (I). ##STR1## R.sup.1 is a hydrogen atom, a halogen atom or a (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkoxy, fluoromethoxy or trifluoromethyl radical, R.sup.2 is a hydrogen or halogen atom, R.sup.3 is selected from hydrogen, (C.sub.1 -C.sub.4) alkyl, N,N-dialkylamino alkyl, (C.sub.3 -C.sub.12) cycloalkyl, methylcyclohexyl, hydroxycyclohexyl, cycloalkylmethyl, piperidyl, alkyl substituted piperidyl or N-benzyl-substituted pipperidyl, R.sup.4 is a hydrogen or halogen atom or a (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkoxy, fluoromethoxy or trifluoromethyl radical, and n is 1, 2 or 3. The invention also provides novel riminophenazines of general formula (I), their preparation, and compositions containing them.

REFERENCES:
patent: 2875204 (1959-02-01), Barry et al.
patent: 2943089 (1960-06-01), Barry et al.
patent: 2946792 (1960-07-01), Barry et al.
patent: 2948726 (1960-08-01), Barry et al.
patent: 3499899 (1970-03-01), Girard et al.
patent: 3592814 (1971-07-01), Barry et al.
patent: 4859667 (1989-08-01), Lau et al.
Anderson et al., Biochem. Pharmacol., 1993, vol. 46, No. 11, pp. 2029-2038.
Anderson et al., Toxicol. Appl. Pharmacol., 1994, vol. 125, pp. 176-183.
Anderson et al., Biochem. Pharmacol., 1988, vol. 37, No. 24, pp. 4635-4641.
Banerjee, et al. Chemotherapy, 1976, vol. 22, No. 3, pp. 242-252.
Barry, Chem. Abs 53, 10546(b), 1958.
Barry et al., Leprosy Review, 1965, vol. 36, pp. 3-7.
Belcher et al., British Journal of Diseases of the Chest, 1970, vol. 64, No. 3, pp. 161-163.
Franzblau et al., Antimicrobial Agents and Chemotherapy, vol. 33, No. 11, Nov. 1979, pp. 2004-2005.
Geeta at al., Tubercle and Lung Disease, 1994, vol. 74, Supplement 1, pp. 25-26.
Hagan et al., Leprosy Review, 1979, vol. 50, pp. 129-134.
Il'yushonok et al., Teor. Eksp. Khim., 1977, vol. 13, No. 6, pp. 763-768.
Kondratenko, et al., Teor. Eksp. Khim., 1977, vol. 13, No. 2, pp. 262-262.
Krajewska et al., Journ. Infect. Dis., 1993, vol. 167, No. 4, pp. 899-904.
Ludwig et al., Chem. Ber., 1982, vol. 115, No. 6, pp. 2380-2383.
O'Connor et al., Biochemical Society Transactions (1995) 23, p. 357S.
O'Sullivan et al., J. Med. Chem., 1988, vol. 31, pp. 567-572.
O'Sullivan et al., Biochemical Society Transactions, 1990, 18(2), pp. 346-347.
O'Sullivan et al., Health Cooperation Papers, 1992, No. 12, pp. 191-197.
Ott et al., Monatsh. Chem., 1976, vol. 107, No. 4, pp. 879-888.
Pettit et al., International Journal of Leprosy and Other Mycobacterial Diseases, 1966, vol. 34, No. 4, pp. 391-397.
Van Landingham et al., International Journal of Leprosy, 1993, vol. 61, No. 61, No. 3, pp. 406-414.
Van Rensburg et al., Cancer Research, 1993, vol. 53, No. 2, pp. 318-329.
Van Rensburg et al., International Journal Oncology, 1993, No. 3, pp. 1011-1013.
Van Rensburg et al., International Journal Oncology, 1994, vol. 14, No. 4, pp. 1115-1119.
Van Rensburg et al., Cancer Letters, 1994, vol. 85, No. 1, pp. 59-63.

Affiliated with

Also associated with

Rating

MDR resistance treatment and novel pharmaceutically active rimin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with MDR resistance treatment and novel pharmaceutically active rimin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MDR resistance treatment and novel pharmaceutically active rimin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2199357